{"id":"NCT04103450","sponsor":"Urovant Sciences GmbH","briefTitle":"Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia","officialTitle":"A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-19","primaryCompletion":"2022-07-29","completion":"2022-07-29","firstPosted":"2019-09-25","resultsPosted":"2024-08-21","lastUpdate":"2024-08-21"},"enrollment":276,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder"],"interventions":[{"type":"DRUG","name":"Vibegron","otherNames":["RVT-901","MK-4618","KRP-114V","URO-901"]}],"arms":[{"label":"Vibegron","type":"EXPERIMENTAL"}],"summary":"This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).","primaryOutcome":{"measure":"Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%)","timeFrame":"Up to Week 52","effectByArm":[{"arm":"52-Week Vibegron Group","deltaMin":2,"sd":null},{"arm":"28-Week Vibegron Group","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"45 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":35,"countries":["United States","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":142},"commonTop":["COVID-19","Hypertension"]}}